Publication | Open Access
Once-weekly semaglutide for patients with type 2 diabetes: a cost-effectiveness analysis in the Netherlands
40
Citations
32
References
2019
Year
Once-weekly semaglutide is cost-effective versus insulin glargine U100, and dominant versus dulaglutide 0.75 and 1.5 mg for the treatment of type 2 diabetes, and represents a good use of healthcare resources in the Netherlands.
| Year | Citations | |
|---|---|---|
Page 1
Page 1